

Manmeet S Ahluwalia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8997801/publications.pdf>

Version: 2024-02-01

131
papers

5,786
citations

93792

39
h-index

104191

69
g-index

154
all docs

154
docs citations

154
times ranked

8201
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors. <i>Seminars in Cancer Biology</i> , 2022, 82, 162-175.	4.3	58
2	Sex Differences in Glioblastoma Immunotherapy Response. <i>NeuroMolecular Medicine</i> , 2022, 24, 50-55.	1.8	11
3	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	3.2	67
4	Quantitation of terameprocol in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 209, 114525.	1.4	0
5	Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 499-507.	1.4	1
6	Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study. <i>Cancer</i> , 2022, 128, 1429-1438.	2.0	21
7	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2022, 24, 855-871.	0.6	38
8	Surgery, Stereotactic Radiosurgery, and Systemic Therapy in the Management of Operable Brain Metastasis. <i>Neurologic Clinics</i> , 2022, 40, 421-436.	0.8	9
9	Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases. <i>Scientific Reports</i> , 2022, 12, 4567.	1.6	8
10	Executive summary of American Radium Society's appropriate use criteria for the postoperative management of lower grade gliomas. <i>Radiotherapy and Oncology</i> , 2022, 170, 79-88.	0.3	2
11	Hospitalization rates from radiotherapy complications in the United States. <i>Scientific Reports</i> , 2022, 12, 4371.	1.6	5
12	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	0.6	39
13	Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2022, 158, 341-348.	1.4	5
14	Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 251-263.	0.6	24
15	Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases. <i>Scientific Reports</i> , 2021, 11, 7490.	1.6	8
16	Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases. <i>Cancers</i> , 2021, 13, 3682.	1.7	14
17	Impact of MRI timing on tumor volume and anatomic displacement for brain metastases undergoing stereotactic radiosurgery. <i>Neuro-Oncology Practice</i> , 2021, 8, 674-683.	1.0	3
18	Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases. <i>Neuro-Oncology Practice</i> , 2021, 8, 662-673.	1.0	6

#	ARTICLE	IF	CITATIONS
19	RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis. <i>Neuro-Oncology Advances</i> , 2021, 3, iii20-iii20.	0.4	0
20	OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance. <i>Neuro-Oncology Advances</i> , 2021, 3, iii15-iii16.	0.4	0
21	Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases. <i>Scientific Reports</i> , 2021, 11, 18174.	1.6	15
22	Comparative efficacy of treatments for brain metastases from non-small-cell lung cancer without an EGFR-mutation/ALK-rearrangement: a systematic review and network meta-analysis. <i>World Neurosurgery</i> , 2021, 158, e87-e87.	0.7	2
23	Systematic evaluation and plan quality assessment of the Leksell [®] gamma knife [®] lightning dose optimizer. <i>Medical Dosimetry</i> , 2021, , .	0.4	10
24	Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance. <i>Discover Oncology</i> , 2021, 12, 48.	0.8	7
25	An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa152.	0.4	1
26	Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab166.	0.4	5
27	Factors associated with unplanned readmissions and costs following resection of brain metastases in the United States. <i>Scientific Reports</i> , 2021, 11, 22152.	1.6	3
28	Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation/ALK Rearrangement: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 739765.	1.3	6
29	Impact of EGFR mutation and ALK rearrangement on the outcomes of non-“small cell lung cancer patients with brain metastasis. <i>Neuro-Oncology</i> , 2020, 22, 267-277.	0.6	22
30	Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases. <i>Journal of Neurosurgery</i> , 2020, 132, 503-511.	0.9	42
31	Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery. <i>Radiotherapy and Oncology</i> , 2020, 142, 168-174.	0.3	29
32	Epstein-Barr virus-associated primary central nervous system lymphoma in a patient with diffuse cutaneous systemic sclerosis on long-term mycophenolate mofetil. <i>Joint Bone Spine</i> , 2020, 87, 163-166.	0.8	6
33	Medical management of brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa015.	0.4	15
34	Management of brain metastases according to molecular subtypes. <i>Nature Reviews Neurology</i> , 2020, 16, 557-574.	4.9	104
35	Can Tumor Location on Pre-treatment MRI Predict Likelihood of Pseudo-Progression vs. Tumor Recurrence in Glioblastoma?â€”A Feasibility Study. <i>Frontiers in Computational Neuroscience</i> , 2020, 14, 563439.	1.2	1
36	Current approaches to the management of brain metastases. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 279-299.	12.5	276

#	ARTICLE	IF	CITATIONS
37	Radiogenomic-Based Survival Risk Stratification of Tumor Habitat on Gd-T1w MRI Is Associated with Biological Processes in Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 1866-1876.	3.2	67
38	ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. <i>Clinical Cancer Research</i> , 2020, 26, 2789-2799.	3.2	130
39	Highlights of the 2019 Society for Neuro-Oncology Inaugural Brain Metastases Conference: establishing a dedicated meeting to address an unmet need in the field. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa036.	0.4	0
40	HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa136.	0.4	6
41	Tumor Habitat-derived Radiomic Features at Pretreatment MRI That Are Prognostic for Progression-free Survival in Glioblastoma Are Associated with Key Morphologic Attributes at Histopathologic Examination: A Feasibility Study. <i>Radiology: Artificial Intelligence</i> , 2020, 2, e190168.	3.0	26
42	SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expression in glioma stem cells. <i>EMBO Molecular Medicine</i> , 2020, 12, e12291.	3.3	35
43	Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 73-79.	3.2	12
44	Phase II study of Dovitinib in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 359-368.	1.4	29
45	The Role of Checkpoint Inhibitors in Glioblastoma. <i>Targeted Oncology</i> , 2019, 14, 375-394.	1.7	30
46	Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1106-1112.	0.4	39
47	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2019, 21, 571-584.	0.6	114
48	Quality of life outcomes in patients presenting for evaluation of CNS tumors. <i>Neurology: Clinical Practice</i> , 2019, 9, 32-40.	0.8	2
49	Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1099-1105.	0.4	8
50	The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. <i>Neuro-Oncology</i> , 2019, 21, 1060-1068.	0.6	76
51	Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. <i>Neuro-Oncology</i> , 2019, 21, 659-668.	0.6	42
52	Current Treatment Options for Breast Cancer Brain Metastases. <i>Current Treatment Options in Oncology</i> , 2019, 20, 19.	1.3	10
53	Upfront Magnetic Resonance Imaging-Guided Stereotactic Laser-Ablation in Newly Diagnosed Glioblastoma: A Multicenter Review of Survival Outcomes Compared to a Matched Cohort of Biopsy-Only Patients. <i>Neurosurgery</i> , 2019, 85, 762-772.	0.6	52
54	Brain metastases. <i>Nature Reviews Disease Primers</i> , 2019, 5, 5.	18.1	579

#	ARTICLE	IF	CITATIONS
55	Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight, 2019, 4, .	2.3	82
56	The Evolving Landscape of Brain Metastasis. Trends in Cancer, 2018, 4, 176-196.	3.8	194
57	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. Oncologist, 2018, 23, 1199-1209.	1.9	42
58	Systemic therapy for brain metastases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 149, 137-153.	1.0	23
59	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiotherapy and Oncology, 2018, 126, 511-518.	0.3	18
60	Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma. Scientific Reports, 2018, 8, 7.	1.6	113
61	Risk Factors for Malignant Transformation of Low-Grade Glioma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 965-971.	0.4	64
62	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e33-e42.	5.1	42
63	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e20-e32.	5.1	87
64	Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma. World Neurosurgery, 2018, 116, e147-e161.	0.7	8
65	Phase I Trial of Radiosurgery Dose Escalation Plus Bevacizumab in Patients With Recurrent/Progressive Glioblastoma. Neurosurgery, 2018, 83, 385-392.	0.6	20
66	Shape Features of the Lesion Habitat to Differentiate Brain Tumor Progression from Pseudoprogression on Routine Multiparametric MRI: A Multisite Study. American Journal of Neuroradiology, 2018, 39, 2187-2193.	1.2	61
67	Novel Systemic Treatments for Brain Metastases From Lung Cancer. Current Treatment Options in Neurology, 2018, 20, 48.	0.7	6
68	Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?. Journal of Clinical Oncology, 2018, 36, 483-491.	0.8	151
69	Management of Brain Metastases in the New Era of Checkpoint Inhibition. Current Neurology and Neuroscience Reports, 2018, 18, 70.	2.0	25
70	Expression of LC3B and FIP200/Atg17 in brain metastases of breast cancer. Journal of Neuro-Oncology, 2018, 140, 237-248.	1.4	7
71	Recent advances in managing brain metastasis. F1000Research, 2018, 7, 1772.	0.8	63
72	Management of Brain Metastases in Tyrosine Kinase Inhibitor- and EGFR-Positive Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. Journal of Clinical Oncology, 2017, 35, 1070-1077.	0.8	372

#	ARTICLE	IF	CITATIONS
73	The impact of tumor biology on survival and response to radiation therapy among patients with non-small cell lung cancer brain metastases. <i>Practical Radiation Oncology</i> , 2017, 7, e263-e273.	1.1	20
74	Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. <i>Cancer</i> , 2017, 123, 2283-2293.	2.0	51
75	The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies. <i>Journal of Neuro-Oncology</i> , 2017, 133, 357-368.	1.4	102
76	The Prognostic Role of Tumor Volume in the Outcome of Patients with Single Brain Metastasis After Stereotactic Radiosurgery. <i>World Neurosurgery</i> , 2017, 104, 229-238.	0.7	15
77	Targeted Treatment of Brain Metastases. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 37.	2.0	28
78	Treatment of Glioblastoma in Older Adults. <i>Current Oncology Reports</i> , 2017, 19, 81.	1.8	45
79	Prediction of new brain metastases after radiosurgery: validation and analysis of performance of a multi-institutional nomogram. <i>Journal of Neuro-Oncology</i> , 2017, 135, 403-411.	1.4	30
80	Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival. <i>Clinical Cancer Research</i> , 2017, 23, 7059-7071.	3.2	26
81	Cumulative Intracranial Tumor Volume and Number of Brain Metastasis as Predictors of Developing New Lesions After Stereotactic Radiosurgery for Brain Metastasis. <i>World Neurosurgery</i> , 2017, 106, 666-675.	0.7	12
82	First follow-up radiographic response is one of the predictors of local tumor progression and radiation necrosis after stereotactic radiosurgery for brain metastases. <i>Cancer Medicine</i> , 2017, 6, 2076-2086.	1.3	16
83	Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 449-458.	1.4	8
84	Intracranial and Systemic Response to Alectinib in a Patient with RET-KIF5B Oncogenic Fusion. <i>Journal of Thoracic Oncology</i> , 2017, 12, e98-e99.	0.5	7
85	Targeted therapy of brain metastases: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 781-796.	1.4	46
86	CMET-01. EFFICACY AND OUTCOME OF ANTI-PD1 THERAPY IN PATIENTS WITH LUNG CANCER BRAIN METASTASIS. <i>Neuro-Oncology</i> , 2017, 19, vi39-vi39.	0.6	1
87	An Excellent Clinical Outcome with Stereotactic Radiosurgery in a Geriatric Patient with Multiple and Recurrent Brain Metastases. <i>Cureus</i> , 2017, 9, e1979.	0.2	0
88	Targeted Therapy in Brain Metastases: Ready for Primetime?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e123-e130.	1.8	35
89	Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e116-e122.	1.8	65
90	BMET-16. REVISED GRADED PROGNOSTIC ASSESSMENT FOR NON-SMALL CELL LUNG CANCER (NSCLC) BRAIN METASTASES (BM) IN THE ERA OF MOLECULAR PROFILING. <i>Neuro-Oncology</i> , 2016, 18, vi29-vi29.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1339-1352.	2.0	105
92	Association Between Radiation Necrosis and Tumor Biology After Stereotactic Radiosurgery for Brain Metastasis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 1060-1069.	0.4	109
93	A cure is possible: a study of 10-year survivors of brain metastases. <i>Journal of Neuro-Oncology</i> , 2016, 129, 545-555.	1.4	25
94	Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism. <i>Neuro-Oncology Practice</i> , 2016, 3, 87-96.	1.0	26
95	Treatment of Large Brain Metastases With Stereotactic Radiosurgery. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 186-195.	0.8	20
96	Management of Brain Metastasis in Patients With Pulmonary Neuroendocrine Carcinomas. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 566-572.	0.8	9
97	Principles of pharmacotherapy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 149-162.	1.0	1
98	Recurrent venous thromboembolism in glioblastoma. <i>Thrombosis Research</i> , 2016, 137, 184-188.	0.8	45
99	The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. <i>Neuro-Oncology</i> , 2016, 18, 153-159.	0.6	86
100	Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e116-e122.	1.8	28
101	Targeted Therapy in Brain Metastases: Ready for Primetime?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e123-e130.	1.8	13
102	Targeted and Immunotherapeutic Approaches in Brain Metastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 67-74.	1.8	16
103	Whole-Brain Radiotherapy and Stereotactic Radiosurgery in Brain Metastases: What Is the Evidence?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e99-e104.	1.8	14
104	Phase I dose-escalation study of the PI3K/mTOR inhibitor voxalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. <i>Neuro-Oncology</i> , 2015, 17, 1275-1283.	0.6	61
105	Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. <i>Journal of Neuro-Oncology</i> , 2015, 122, 111-119.	1.4	22
106	Differential Connexin Function Enhances Self-Renewal in Glioblastoma. <i>Cell Reports</i> , 2015, 11, 1031-1042.	2.9	100
107	Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 121, 297-302.	1.4	42
108	Bevacizumab in high-grade gliomas: past, present, and future. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 387-397.	1.1	18

#	ARTICLE	IF	CITATIONS
109	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1386-1392.	0.6	50
110	Growth Factor Receptor Fusions Predict Therapeutic Sensitivity. <i>Clinical Cancer Research</i> , 2015, 21, 3105-3107.	3.2	0
111	Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases. <i>Journal of Neuro-Oncology</i> , 2015, 124, 485-491.	1.4	23
112	Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. <i>Lancet Oncology</i> , The, 2015, 16, e595-e603.	5.1	170
113	Prognostic scores for brain metastasis patients: use in clinical practice and trial design. <i>Chinese Clinical Oncology</i> , 2015, 4, 18.	0.4	47
114	Phase II trial of patupilone in patients with brain metastases from breast cancer. <i>Neuro-Oncology</i> , 2014, 16, 579-583.	0.6	23
115	Medical therapy of gliomas. <i>Journal of Neuro-Oncology</i> , 2014, 119, 503-512.	1.4	15
116	Brain metastasis and treatment. <i>F1000prime Reports</i> , 2014, 6, 114.	5.9	44
117	Recurrent or refractory primary central nervous lymphoma: therapeutic considerations. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1109-1119.	1.1	12
118	Challenges With the Diagnosis and Treatment of Cerebral Radiation Necrosis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 449-457.	0.4	251
119	Chemotherapy for Brain Tumors. , 2012, , 94-104.		0
120	Therapeutic targeting of VEGF in the treatment of glioblastoma. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 973-984.	1.5	35
121	Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1247-1266.	1.9	50
122	Flow cytometry as a diagnostic tool in lymphomatous or leukemic meningitis. <i>Cancer</i> , 2012, 118, 1747-1753.	2.0	43
123	Primary Central Nervous System Lymphoma in Elderly Patients: Clinical Outcomes and Prognosis. <i>Blood</i> , 2012, 120, 5083-5083.	0.6	0
124	Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 653-656.	1.1	38
125	Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2011, 102, 317-321.	1.4	35
126	Role of tyrosine kinase inhibitors in the management of high-grade gliomas. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1739-1748.	1.1	4

#	ARTICLE	IF	CITATIONS
127	Primary Central Nervous System Lymphoma. Current Treatment Options in Neurology, 2010, 12, 347-359.	0.7	15
128	Progress on Antiangiogenic Therapy for Patients with Malignant Glioma. Journal of Oncology, 2010, 2010, 1-14.	0.6	45
129	Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies. Cancer Letters, 2010, 298, 139-149.	3.2	104
130	Thalidomide in Multiple Myeloma - A Community Hospital Experience.. Blood, 2005, 106, 5140-5140.	0.6	1
131	Successful Use of Recombinant Factor VIIa in Reversal of Life Threatening Bleeding Caused by Coagulopathy.. Blood, 2005, 106, 4077-4077.	0.6	0